Analog kefir production with a low phenylalanine for Phenylketonuria
Authors
Abstract:
Phenylketonuria (PKU) is one of the most prevalent types of hereditary metabolic disorders which is caused due to an absence or reduction of the activity of the Phenylalanine hydroxylase enzyme in the liver which in turn, inhibits the transformation of phenylalanine (Phe) to tyrosine. In clinical terms, this disorder is displayed with severe, permanent and irreversible mental retardation. This research was aimed at development of a highly nutrient and acceptable suitable analogue Kefir drink for these patients. The mentioned drink is based on milk permeate, cream powder and includes glycomacropeptide (GMP) as a source of protein, starter as a fermentation source, the trance glutamines (TG) enzyme, dough stabilizer and modified corn starch as tissue maker, salt and water. The GMP used in this analogue drink is intended for enrichment of the product and therefore it was added by 3% to one formula. The aforementioned sample had a lower calculated amount of pH and alcohol percentage in comparison with the 16 samples which did not have GMP. The results of this study showed that the analog kefir has a low level of phenylalanine (30.40 mg/100g) and in that regard, it can be considered to be useful for patients with PKU.
similar resources
Phenylalanine Metabolism: Phenylketonuria
The hydroxylase is a trimer of approximately 150 kDa of identical subunits and is located predominantly in the liver. The enzyme has been mapped to human chromosome 12q22-24.1, where the gene comprises 13 exons extending over 90 kb of genomic DNA. Deletions in the gene are not common. A frequent cause among northern Europeans (~40%) is a G-to-A transition at the 5′ donor splice site in intron 1...
full textMaternal phenylketonuria: abnormal baby despite low phenylalanine diet during pregnancy.
During a screening programme of 10000 pregnant women by the Guthrie test, a previously unrecognised phenylketonuric woman was detected. A low phenylalanine diet introduced from the 16th week of gestation failed to prevent fetal abnormality and mental retardation. Maternal phenylketonuria requires earlier diagnosis than can be achieved at the initial antenatal clinic visit if its teratogenic eff...
full textPreparation of a Selective L-Phenylalanine Imprinted Polymer Implicated in Patients with Phenylketonuria
Abstract Background: Molecular imprinting is a method for synthesizing polymers with structure-selective adsorption properties with applications such as, selectivity binding, drug delivery systems and anti-bodies. The present study aims at optimizing the preparation of molecularly imprinted polymer (MIP) against l-phenylalanine, in order to increase phenylalanine-binding in Enzymatic Intestinal...
full textA different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.
Phenylketonuria (PKU), with its associated hyperphenylalaninemia (HPA) and mental retardation, is a classic genetic disease and the first to have an identified chemical cause of impaired cognitive development. Treatment from birth with a low phenylalanine diet largely prevents the deviant cognitive phenotype by ameliorating HPA and is recognized as one of the first effective treatments of a gen...
full textSignificant phenylalanine hydroxylation in vivo in patients with classical phenylketonuria.
Indirect measurements have previously suggested that patients with classical phenylketonuria (PKU) do not convert significant amounts of phenylalanine to tyrosine. Low-dose continuous infusion techniques employing [2H5]phenylalanine and [2H2]tyrosine were used to quantitate in vivo phenylalanine hydroxylation in 10 subjects with classical phenylketonuria, 2 with hyperphenylalaninemia (HPA), and...
full textMy Resources
Journal title
volume 5 issue 2
pages 111- 120
publication date 2017-06-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023